
Life Sciences

Cahill serves as a partner and advisor to emerging and top life sciences companies. Our practice also includes advising top tier financial firms active in the sector. The breadth and scope of our life sciences practice is evidenced by the range of complex scientific, commercial, intellectual property, regulatory and transactional matters we handle. Thus, we help these clients navigate the full spectrum of significant issues across intellectual property strategy and licensing; research, development and commercialization collaborations; financings; mergers and acquisitions; corporate governance; and corporate investigations.

We seek to go beyond traditional representation and add value by actively participating in strategic decision-making and valuation enhancement. Our clients utilize our team's experience to establish or challenge "freedom to operate" opinions and address other intellectual property issues, to negotiate with regulators on marketing-related issues, and to help customers, investors, partners, licensees and others to better understand and recognize the value of a company's assets, skill set, and strategic and scientific objectives.

We represent and advise firms in every stage of development, from the laboratory/research phase through the clinical, regulatory, marketing and exit phases, and in a broad range of fields including biotechnology, diagnostics, drug delivery, licensing, medical devices, and pharmaceuticals.

Our lawyers also guide both financial clients and life sciences companies through the due diligence process and the structuring and execution of transactions associated with asset acquisition financing, mergers and acquisitions and other strategic transactions, and public and private offerings of debt and equity securities.

We also bring both our extensive intellectual property experience and our peerless strength in finance to bear in the context of mergers and acquisitions, research and development collaborations, commercialization agreements, revenue purchase agreements, royalty-based financings, and IP-focused restructurings.

In adverse intellectual property-focused matters, our life sciences group has secured significant victories in lawsuits and arbitrations, including a landmark First Amendment victory on behalf of Amarin Pharma against the FDA that enables Amarin to truthfully and non-misleadingly promote to doctors and other healthcare professionals an off-label use of its omega-3 drug Vascepa.